Poly-γ-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus-like particles provide effective protection from Japanese encephalitis virus

Clinical and Vaccine Immunology

Volumn 19, Issue 1, 2012, Pages 17-22

  Okamoto, Shigefumi ^a   Yoshii, Hironori ^a,b   Matsuura, Masaaki ^a,b   Kojima, Asato ^c   Ishikawa, Toyokazu ^b   Akagi, Takami ^d,e   Akashi, Mitsuru ^d,e   Takahashi, Michiaki ^b   Yamanishi, Koichi ^a   Mori, Yasuko ^a,f  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b Osaka University   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^f KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; JAPANESE ENCEPHALITIS VACCINE; NANOPARTICLE; NEUTRALIZING ANTIBODY; POLY(GAMMA GLUTAMIC ACID) NANOPARTICLE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; FEMALE; IMMUNITY; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM; ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; FEMALE; JAPANESE ENCEPHALITIS VACCINES; MICE; MICE, INBRED BALB C; NANOPARTICLES; POLYGLUTAMIC ACID; SURVIVAL ANALYSIS; VACCINATION;

EID: 84855705399     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05412-11     Document Type: Article

References (35)

1. Akagi T, Higashi M, Kaneko T, Kida T, Akashi M. 2005. In vitro enzymatic degradation of nanoparticles prepared from hydrophobically-modified poly(gamma-glutamic acid). Macromol. Biosci. 5:598-602. (Pubitemid 41020250)
2. Akagi T, Kaneko T, Kida T, Akashi M. 2005. Preparation and characterization of biodegradable nanoparticles based on poly(gamma-glutamic acid) with l-phenylalanine as a protein carrier. J. Control. Release 108:226-236. (Pubitemid 41608656)
3. Akagi T, Wang X, Uto T, Baba M, Akashi M. 2007. Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly-(amino acid) derivatives. Biomaterials 28:3427-3436. (Pubitemid 46729729)
4. Bista MB, et al. 2001. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 358:791-795. (Pubitemid 32868728)
5. Chen HW, et al. 1999. Screening of protective antigens of Japanese encephalitis virus byDNAimmunization: a comparative study with conventional viral vaccines. J. Virol. 73:10137-10145.
6. De Gregorio E, Tritto E, Rappuoli R. 2008. Alum adjuvanticity: unraveling a century old mystery. Eur. J. Immunol. 38:2068-2071.
7. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. 2008. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453:1122-1126. (Pubitemid 351871731)
8. Ferguson M, Kurane I, Wimalaratne O, Shin J, Wood D. 2007. WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1-2 June 2006. Vaccine 25:5233-5243. (Pubitemid 46977544)
9. Franchi L, Nunez G. 2008. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur. J. Immunol. 38:2085-2089.
10. Gubler DJ, Kuno G, Markoff L. 2007. Flaviviruses, p 1153-1252. In Knipe DM, et al (ed), Fields virology, 5th ed. Lippincott-Raven, Philadelphia, PA.
11. Infectious Diseases Surveillance Center. 2005.Immunization schedule, Japan 2005, July 29. Infectious Diseases Surveillance Center, Tokyo, Japan. http://idsc.nih.go.jp/vaccine/dschedule/ImmEN-050729rev.gif.
12. Kojima A, et al. 2003. Stable high-producer cell clone expressing viruslike particles of the Japanese encephalitis virus e protein for a secondgeneration subunit vaccine. J. Virol. 77:8745-8755. (Pubitemid 36936086)
13. Konishi E, Mason PW. 1993. Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein. J. Virol. 67:1672-1675. (Pubitemid 23067678)
14. Konishi E, et al. 1992. Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology 188:714-720.
15. Konishi E, Yamaoka M, Khin Sane W, Kurane I, Mason PW. 1998. Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. J. Virol. 72:4925-4930. (Pubitemid 28215671)
16. Kool M, et al. 2008. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 205:869-882. (Pubitemid 351549884)
17. Kurane I, Takasaki T. 2000. Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains. Vaccine 18(Suppl. 2):33-35. (Pubitemid 30252000)
18. Mackenzie JS, et al. 2001. Emerging viral diseases of Southeast Asia and the Western Pacific. Emerg. Infect. Dis. 7:497-504. (Pubitemid 32726817)
19. Mackenzie JS, Johansen CA, Ritchie SA, van den Hurk AF, Hall RA. 2002. Japanese encephalitis as an emerging virus: the emergence and spread of Japanese encephalitis virus in Australasia. Curr. Top. Microbiol. Immunol. 267:49-73. (Pubitemid 34411358)
20. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R. 2010. New adjuvants for human vaccines. Curr. Opin. Immunol. 22:411-416.
21. Mutoh E, et al. 2004. Japanese encephalitis subunit vaccine composed of virus-like envelope antigen particles purified from serum-free medium of a high-producer J12#26 cell clone. Vaccine 22:2599-2608. (Pubitemid 38757363)
22. Nakayama T, Onoda K. 2007. Vaccine adverse events reported in postmarketing study of the Kitasato Institute from 1994 to 2004. Vaccine 25:570-576. (Pubitemid 44856088)
23. Ogata T. 1971. Methods for testing potency in animals and their significance, p 65-71. In Hammon WM, Kitaoka M, DownsWG(ed), Immunization for Japanese encephalitis. Igaku Shoin Ltd., Tokyo, Japan.
24. Ohrr H, et al. 2005. Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a casecontrol study. Lancet 366:1375-1378. (Pubitemid 41443404)
25. Ohtaki E, Matsuishi T, Hirano Y, Maekawa K. 1995. Acute disseminated encephalomyelitis after treatment with Japanese B encephalitis vaccine (Nakayama-Yoken and Beijing strains). J. Neurol. Neurosurg. Psychiatry 59:316-317.
26. Okamoto S, et al. 2007. Influenza hemagglutinin vaccine with poly(gammaglutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity. Vaccine 25:8270-8278. (Pubitemid 350087384)
27. Okamoto S, et al. 2008. Single dose of inactivated Japanese encephalitis vaccine with poly(gamma-glutamic acid) nanoparticles provides effective protection from Japanese encephalitis virus. Vaccine 26:589-594.
28. Shih IL, Van YT, Yeh LC, Lin HG, Chang YN. 2001. Production of a biopolymer flocculant from Bacillus licheniformis and its flocculation properties. Bioresour. Technol. 78:267-272. (Pubitemid 32288820)
29. Solomon T, Mallewa M. 2001. Dengue and other emerging flaviviruses. J. Infect. 42:104-115. (Pubitemid 32633350)
30. Srivastava AK, et al. 2001. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 19:4557-4565. (Pubitemid 32718682)
31. Tanimoto H, et al. 2001. Natto mucilage containing poly-gammaglutamic acid increases soluble calcium in the rat small intestine. Biosci. Biotechnol. Biochem. 65:516-521. (Pubitemid 33615913)
32. Uto T, et al. 2011. Comparative activity of biodegradable nanoparticles with aluminum adjuvants: antigen uptake by dendritic cells and induction of immune response in mice. Immunol. Lett. 140:36-43.
33. Uto T, et al. 2011. The induction of innate and adaptive immunity by biodegradable poly(gamma-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway. Biomaterials 32:5206-5212.
34. Uto T, et al. 2007. Targeting of antigen to dendritic cells with poly(gammaglutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J. Immunol. 178:2979-2986. (Pubitemid 46333177)
35. Yoshikawa T, et al. 2008. Nanoparticles built by self-assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells. Vaccine 26:1303-1313.